Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

被引:0
|
作者
Robert S. Ames
Henry M. Sarau
Johathan K. Chambers
Robert N. Willette
Nambi V. Aiyar
Anne M. Romanic
Calvert S. Louden
James J. Foley
Charles F. Sauermelch
Robert W. Coatney
Zhaohui Ao
Jyoti Disa
Stephen D. Holmes
Jeffrey M. Stadel
John D. Martin
Wu-Schyong Liu
George I. Glover
Shelagh Wilson
Dean E. McNulty
Catherine E. Ellis
Nabil A. Elshourbagy
Usman Shabon
John J. Trill
Douglas W. P. Hay
Eliot H. Ohlstein
Derk J. Bergsma
Stephen A. Douglas
机构
[1] Departments of Molecular Biology,
[2] Departments of Pulmonary and Cardiovascular Pharmacology,undefined
[3] ,undefined
[4] Departments of Functional Gene Analysis,undefined
[5] Departments of Pathology,undefined
[6] Laboratory Animal Sciences,undefined
[7] Departments of Immunology,undefined
[8] Protein Biochemistry and ,undefined
[9] Gene Expression Sciences,undefined
[10] Smith Kline Beecham Pharmaceuticals,undefined
来源
Nature | 1999年 / 401卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Urotensin-II (U-II) is a vasoactive ‘somatostatin-like’ cyclic peptide which was originally isolated from fish spinal cords1,2, and which has recently been cloned from man3. Here we describe the identification of an orphan human G-protein-coupled receptor homologous to rat GPR14 (refs 4, 5) and expressed predominantly in cardiovascular tissue, which functions as a U-II receptor. Goby and human U-II bind to recombinant human GPR14 with high affinity, and the binding is functionally coupled to calcium mobilization. Human U-II is found within both vascular and cardiac tissue (including coronary atheroma) and effectively constricts isolated arteries from non-human primates. The potency of vasoconstriction of U-II is an order of magnitude greater than that of endothelin-1, making human U-II the most potent mammalian vasoconstrictor identified so far. In vivo, human U-II markedly increases total peripheral resistance in anaesthetized non-human primates, a response associated with profound cardiac contractile dysfunction. Furthermore, as U-II immunoreactivity is also found within central nervous system and endocrine tissues, it may have additional activities.
引用
收藏
页码:282 / 286
页数:4
相关论文
共 50 条
  • [21] Urotensin-II receptor antagonists
    Carotenuto, A
    Griecio, P
    Rovero, P
    Novellino, E
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (03) : 267 - 275
  • [22] Urotensin-II receptor modulators
    Dhanak, D
    Neeb, MJ
    Douglas, SA
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 99 - 110
  • [23] Urotensin-II receptor antagonists
    Edwards, P
    DRUG DISCOVERY TODAY, 2006, 11 (3-4) : 181 - 181
  • [24] Urotensin-II receptor ligands. From agonist to antagonist activity
    Grieco, P
    Carotenuto, A
    Campiglia, P
    Marinelli, L
    Lama, T
    Patacchini, R
    Santicioli, P
    Maggi, CA
    Rovero, P
    Novellino, E
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) : 7290 - 7297
  • [25] Urotensin-II receptor ligands - Switching from agonist to antagonist activity
    Carotenuto, Alfonso
    Grieco, Paolo
    Campiglia, Pietro
    Marinelli, Luciana
    Rovero, Paolo
    Novellino, Ettore
    Peptides 2004, Proceedings: BRIDGES BETWEEN DISCIPLINES, 2005, : 706 - 707
  • [26] Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat
    Gong, H
    Wang, YX
    Zhu, YZ
    Wang, WW
    Wang, MJ
    Yao, T
    Zhu, YC
    JOURNAL OF APPLIED PHYSIOLOGY, 2004, 97 (06) : 2228 - 2235
  • [27] Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chloropheny)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-7954)
    Croston, GE
    Olsson, R
    Currier, EA
    Burstein, ES
    Weiner, D
    Nash, N
    Severance, D
    Allenmark, SG
    Thunberg, L
    Ma, JN
    Mohell, N
    O'Dowd, B
    Brann, MR
    Hacksell, U
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (23) : 4950 - 4953
  • [28] Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain
    Boucard, AA
    Sauvé, SS
    Guillemette, G
    Escher, E
    Leduc, R
    BIOCHEMICAL JOURNAL, 2003, 370 : 829 - 838
  • [29] Human urotensin-II, the most potent mammalian vasoconstrictor identified, represents a novel therapeutic target in the treatment of cardiovascular disease
    Douglas, S
    Aiyar, NV
    Ohlstein, EH
    Willette, RN
    EUROPEAN HEART JOURNAL, 2000, 21 : 495 - 495
  • [30] Urotensin-II activates Rac-1 and ROS production in pulmonary artery smooth muscle cells involving GPR14 and Gα13 proteins
    Djordjevic, Talija
    Schaefer, Nicola
    Weitnauer, Michael
    Hess, John
    Goerlach, Agnes
    CIRCULATION, 2007, 116 (16) : 8 - 8